Palliative Osimertinib Rechallenge Achieving Rapid Improvement in Leptomeningeal Carcinomatosis After Prior Osimertinib‐Induced ILD

Respirology Case Reports 2026 Open access

Read full text
Authors: Akina Nigi, Keisuke S. Iwamoto, Hidetoshi Itani, Shigeto Kondou
DOI: 10.1002/rcr2.70467
Cited by: 1
References: 1

Abstract

A patient with EGFR-mutant lung cancer developed leptomeningeal carcinomatosis years after osimertinib-induced ILD. With no other treatment options, palliative osimertinib rechallenge led to rapid neurological improvement and radiological response, without ILD recurrence. This case highlights the potential of carefully monitored osimertinib rechallenge for symptomatic relief in exceptional cases.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Brain Metastases and Treatment Management of metastatic bone disease

Publication details

Journal / source
Respirology Case Reports
Publisher
Wiley
Volume
14
Issue
1
Pages
e70467–e70467
Publication date
1 January 2026
Language
EN